Dr. Nathan Sackett has joined CaaMTech’s growing team of scientific advisors as a leading expert on addiction psychiatry. Dr. Sackett is an Acting Assistant Professor at the University of Washington where he helped to establish – and serves as the Director of – the Department of Psychiatry & Behavioral Sciences Center for Novel Therapeutics in Addiction Psychiatry (NTAP). Dr. Sackett’s extensive clinical experience in addiction and other neurological disorders will provide critical insight to CaaMTech as it develops the next generation of neuropsychiatric treatments for a range of intractable conditions.
Dr. Nathan Sackett (MD, MS, RN) attended medical and nursing school at the University of California San Francisco (UCSF) and graduate school at the University of California Berkeley. He completed his adult psychiatry residency and addiction psychiatry fellowship at the University of Washington. Dr. Sackett is now an Acting Assistant Professor at the University of Washington in the Department of Psychiatry and Behavioral Sciences where he splits his time between clinical work and research. In the clinic, Dr. Sackett works primarily outpatient, seeing a range of patients with primary psychiatric issues and substance use disorders. His research focuses on the use of psychedelics to treat substance use disorders.
In 2023, Dr. Sackett helped to launch the Department of Psychiatry & Behavioral Sciences Center for Novel Therapeutics in Addiction Psychiatry (NTAP) at the University of Washington. This research center makes the University of Washington one of the first major academic institutions to officially establish research programs for psychedelic medicines, highlighting the tremendous resurgence of interest in the scientific investigation of psychedelics. Dr. Sackett now serves as the Center’s director.
“I have always been interested in translational research from first principles. I am so excited by CaaMTech’s work – from identifying compounds to thinking about potential clinical applications,” said Dr. Nathan Sackett. “I hope my clinical experience can be leveraged in combination with my clinical trial work to identify treatments that may help my patients and others afflicted by mental illness.”
Dr. Sackett will provide CaaMTech’s growing team of experts in their respective scientific fields with insights into the clinical applications of psychedelic medicines in treating neurological conditions such as Substance Use Disorders, schizophrenia, and severe depression. Dr. Sackett’s expertise in administering psychedelic drugs to patients in clinical settings gives him a unique perspective that will help guide CaaMTech’s foundational scientific research and drug development efforts.
“Nathan brings a unique mix of clinical expertise as an addiction psychiatrist and a researcher, with a focus on improving clinical care,” said Dr. Andrew Chadeayne, CaaMTech CEO. “Our entire team is delighted to have Nathan’s perspective on clinical applications of psychedelics while we build the next generation of psychiatric treatments.”